ABSTRACT
The juxtaposition of two seemingly disparate physiological phenomena within the human body-namely, cancer and pregnancy-may offer profound insights into the intricate interplay between malignancies and the immune system. Recent investigations have unveiled striking similarities between the pivotal processes underpinning fetal implantation and successful gestation and those governing tumor initiation and progression. Notably, a confluence of features has emerged, underscoring parallels between the microenvironment of tumors and the maternal-fetal interface. These shared attributes encompass establishing vascular networks, cellular mobilization, recruitment of auxiliary tissue components to facilitate continued growth, and, most significantly, the orchestration of immune-suppressive mechanisms.Our particular focus herein centers on the phenomenon of immune suppression and its protective utility in both of these contexts. In the context of pregnancy, immune suppression assumes a paramount role in shielding the semi-allogeneic fetus from the potentially hostile immune responses of the maternal host. In stark contrast, in the milieu of cancer, this very same immunological suppression fosters the transformation of the tumor microenvironment into a sanctuary personalized for the neoplastic cells.Thus, the striking parallels between the immunosuppressive strategies deployed during pregnancy and those co-opted by malignancies offer a tantalizing reservoir of insights. These insights promise to inform novel avenues in the realm of cancer immunotherapy. By harnessing our understanding of the immunological events that detrimentally impact fetal development, a knowledge grounded in the context of conditions such as preeclampsia or miscarriage, we may uncover innovative immunotherapeutic strategies to combat cancer.
Subject(s)
Neoplasms , Pregnancy , Animals , Female , Humans , Pregnancy/immunology , Immune Tolerance , Immunotherapy , Neoplasms/immunology , Pregnancy Complications, Neoplastic/immunology , Tumor Microenvironment/immunologyABSTRACT
Breast cancer during pregnancy (PrBC) is a rare tumor with only a little information on its immune landscape. Here, we sought to characterize the cellular composition of the tumor microenvironment (TME) of PrBC and identify its differences from early-onset breast cancer (EOBC) in non-pregnant women. A total of 83 PrBC and 89 EOBC were selected from our Institutional registry and subjected to tumor-infiltrating lymphocytes (TILs) profiling and immunohistochemistry for CD4, CD8, forkhead box P3 (FOXP3), and programmed death-ligand 1 (PD-L1) (clone 22C3). A significantly lower frequency of hormone receptor (HR)-positive tumors was observed in PrBC. The prevalence of low/null PD-L1 and CD8+TILs was higher in PrBC than in the controls, specifically in HR+/HER2- breast cancers. PrBC had a significantly higher risk of relapse and disease-related death, compared to EOBC. The presence of TILs and each TIL subpopulation were significantly associated with disease relapse. Moreover, the death rate was higher in PrBC with CD8+ TILs. The TME of PrBC is characterized by specific patterns of TIL subpopulations with significant biological and prognostic roles. Routine assessment of TILs and TILs subtyping in these patients would be a valid addition to the pathology report that might help identify clinically relevant subsets of women with PrBC.
Subject(s)
Breast Neoplasms , Pregnancy Complications, Neoplastic , Tumor Microenvironment , B7-H1 Antigen , Breast Neoplasms/immunology , Breast Neoplasms/pathology , Female , Humans , Lymphocytes, Tumor-Infiltrating , Neoplasm Recurrence, Local/pathology , Pregnancy , Pregnancy Complications, Neoplastic/immunology , Pregnancy Complications, Neoplastic/pathologyABSTRACT
BACKGROUND: Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. However, patient-identification mostly relies on the trial site itself and is often a time-consuming procedure, which could result in missing out on potentially eligible patients. Pre-selection of those patients using a registry could facilitate the process of eligibility testing and increase the number of identified patients. One aim with the PRAEGNANT registry (NCT02338167) is to identify patients for therapies based on clinical and molecular data. Here, we report eligibility testing for the SHERBOC trial using the German PRAEGNANT registry. METHODS: Heregulin (HRG) has been reported to identify patients with better responses to therapy with the anti-HER3 monoclonal antibody seribantumab (MM-121). The SHERBOC trial investigated adding seribantumab (MM-121) to standard therapy in patients with advanced HER2-negative, hormone receptor-positive (HR-positive) breast cancer and HRG overexpression. The PRAEGNANT registry was used for identification and tumor testing, helping to link potential HRG positive patients to the trial. Patients enrolled in PRAEGNANT have invasive and metastatic or locally advanced, inoperable breast cancer. Patients eligible for SHERBOC were identified by using the registry. Study aims were to describe the HRG positivity rate, screening procedures, and patient characteristics associated with inclusion and exclusion criteria. RESULTS: Among 2769 unselected advanced breast cancer patients, 650 were HER2-negative, HR-positive and currently receiving first- or second-line treatment, thus potentially eligible for SHERBOC at the end of current treatment; 125 patients also met further clinical eligibility criteria (e.g. menopausal status, ECOG). In the first/second treatment lines, patients selected for SHERBOC based on further eligibility criteria had a more favorable prognosis than those not selected. HRG status was tested in 38 patients, 14 of whom (36.8%) proved to be HRG-positive. CONCLUSION: Using a real-world breast cancer registry allowed identification of potentially eligible patients for SHERBOC focusing on patients with HER3 overexpressing, HR-positive, HER2-negative metastatic breast cancer. This approach may provide insights into differences between patients eligible or non-eligible for clinical trials. TRIAL REGISTRATION: Clinicaltrials, NCT02338167 , Registered 14 January 2015 - retrospectively registered.
Subject(s)
Antibodies, Monoclonal/immunology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Neoplasms/pathology , Neuregulin-1/metabolism , Patient Selection , Pregnancy Complications, Neoplastic/pathology , Registries/statistics & numerical data , Adult , Biomarkers, Tumor/immunology , Biomarkers, Tumor/metabolism , Case-Control Studies , Clinical Trials as Topic , Female , Follow-Up Studies , Germany , Humans , Middle Aged , Neoplasms/drug therapy , Neoplasms/immunology , Neoplasms/metabolism , Neuregulin-1/immunology , Pregnancy , Pregnancy Complications, Neoplastic/drug therapy , Pregnancy Complications, Neoplastic/immunology , Pregnancy Complications, Neoplastic/metabolism , Prognosis , Prospective Studies , Survival RateABSTRACT
Pregnant women are particularly susceptible to complications of influenza A virus infection, which may result from pregnancy-induced changes in the function of immune cells, including natural killer (NK) cells. To better understand NK cell function during pregnancy, we assessed the ability of the two main subsets of NK cells, CD56dim, and CD56bright NK cells, to respond to influenza-virus infected cells and tumor cells. During pregnancy, CD56dim and CD56bright NK cells displayed enhanced functional responses to both infected and tumor cells, with increased expression of degranulation markers and elevated frequency of NK cells producing IFN-γ. To better understand the mechanisms driving this enhanced function, we profiled CD56dim and CD56bright NK cells from pregnant and non-pregnant women using mass cytometry. NK cells from pregnant women displayed significantly increased expression of several functional and activation markers such as CD38 on both subsets and NKp46 on CD56dim NK cells. NK cells also displayed diminished expression of the chemokine receptor CXCR3 during pregnancy. Overall, these data demonstrate that functional and phenotypic shifts occur in NK cells during pregnancy that can influence the magnitude of the immune response to both infections and tumors.
Subject(s)
Killer Cells, Natural/immunology , Pregnancy/immunology , Adult , Cells, Cultured , Cohort Studies , Female , Humans , Pregnancy Complications, Infectious/immunology , Pregnancy Complications, Neoplastic/immunologyABSTRACT
Dermatofibromas are common and asymptomatic benign histiocytic tumors. The occurrence in a small number (up to 5 lesions) is frequent. However, the expression "multiple eruptive dermatofibromas" is reserved for the appearance of more than 5 lesions in less than four months. Multiple eruptive dermatofibromas are rare and usually associated with an underlying systemic condition, the most common being autoimmune diseases or HIV infection. Herein we report multiple eruptive dermatofibromas developing in an otherwise healthy pregnant woman. Although the pathogenesis of this condition remains unknown, it is believed to be related to immunological alterations, given the strong association with states of immunosuppression or, in the case of pregnancy, with a state of immunotolerance.
Subject(s)
Histiocytoma, Benign Fibrous/pathology , Pregnancy Complications, Neoplastic/pathology , Skin Neoplasms/pathology , Adult , Female , Histiocytoma, Benign Fibrous/immunology , Humans , Immune Tolerance , Pregnancy , Pregnancy Complications, Neoplastic/immunology , Skin Neoplasms/immunologyABSTRACT
BACKGROUND: Breast cancer is one of the most frequently diagnosed malignancies during pregnancy. Tumours often present characteristics of high malignancy and are hormone receptor negative/HER2 positive or triple negative. In general, pregnancy, including the postpartum period, is associated with a transiently increased risk of developing breast cancer but followed by a long-lasting protective period. Placental metastases are very rare and, thus far, breast cancer metastases in the foetal compartment have not been described. To discuss these apparently contradictory observations, this narrative review resumes immunological and hormonal alterations during pregnancy potentially affecting breast cancer risk as well as tumour growth and behaviour. OBSERVATIONS: Upregulation of breast cancer-associated genes involved in immunological and reproductive processes has been observed in parous women and is potentially responsible for a transiently increased risk in pregnancy. In contrast, maternal immunisation and immunoglobulin production against antigens expressed on trophoblast cells, such as specific glycosylation patterns of mucin-1 or RCAS1-associated truncated glycans, seem to prevent breast cancer development in later years. Animal and human studies indicate that T cells are involved in these processes. Several placenta-derived factors, especially kisspeptin, have direct anti-tumour effects. The pregnancy-related increase of estrogen, progesterone, and other hormones influence growth and characteristics of breast cancer while the role of further placenta-secreted factors is still controversially discussed. CONCLUSION: Several factors and cells are involved in altered breast cancer risk during and after pregnancy and have potential for developing novel treatment strategies in future.
Subject(s)
Breast Neoplasms/pathology , Placenta/pathology , Pregnancy Complications, Neoplastic/pathology , Animals , Breast Neoplasms/immunology , Breast Neoplasms/metabolism , Female , Hormones/metabolism , Humans , Intercellular Signaling Peptides and Proteins/metabolism , Neoplasm Metastasis , Placenta/immunology , Placenta/metabolism , Postpartum Period , Pregnancy , Pregnancy Complications, Neoplastic/immunology , Pregnancy Complications, Neoplastic/metabolism , Prognosis , Risk Assessment , Risk Factors , Signal Transduction , Tumor MicroenvironmentABSTRACT
Despite their abilities to elicit immune responses, both syngeneic tumors and the half-mismatched placenta grow in the host, unlike a tissue allograft that is aggressively rejected. This is because of local and systemic factors that contribute to the immunologic privilege of tumors and the placenta. Checkpoint blockade immunotherapies subvert this privilege, with spectacularly beneficial outcomes in subsets of patients with certain types of cancer. A challenge for the community of scientists and clinicians is to replicate these successes in pregnant patients with cancer, without harm to the placenta. Here we compare and contrast the immunology of cancers and the placenta, and suggest that immunotherapy for pregnant patients with cancer may be a reasonable option, but that this should be explored systematically.
Subject(s)
Immune Privilege/immunology , Immunotherapy/methods , Neoplasms/therapy , Placenta/immunology , Pregnancy Complications, Neoplastic/therapy , Female , HLA Antigens/immunology , Humans , Neoplasms/immunology , Neoplasms/metabolism , Placenta/metabolism , Pregnancy , Pregnancy Complications, Neoplastic/immunology , Pregnancy Complications, Neoplastic/metabolism , T-Lymphocytes/immunologyABSTRACT
BACKGROUND: Pregnancy-associated breast cancer (PABC) refers to breast cancers (BC) diagnosed during pregnancy or shortly after birth. Although the inflammatory environment of post-partum PABC cases (designed as PP-PABC) may be deleterious, so far PP-PABC have scarcely been distinguished from breast cancers diagnosed during pregnancy. Furthermore, whether PP-PABC cases have an enhanced immune infiltration remains unknown. We investigated chemosensitivity, immune infiltration and survival of PP-PABC patients treated by neoadjuvant chemotherapy (NAC) compared to non-PABC matched BC patients. MATERIALS AND METHODS: We identified PP-PABC cases among a cohort of 1199 invasive BC treated with NAC between 2002 and 2012. Each PP-PABC case was matched with 3 non-PABC controls, according to age and pathological breast cancer subtype. Microbiopsy specimens and paired surgical samples were evaluated for stromal lymphocyte infiltration. Association of clinical and pathological factors with pathological complete response (pCR) and disease-free survival (DFS) was assessed by univariate and multivariate analyses. RESULTS: Our final population study was composed of 116 patients (29â¯PP-PABC and 87 non-PABC). Median follow-up was of 49.0 and 29.3 months, respectively. After NAC, pCR rates (pâ¯=â¯0.64), post-NAC immune infiltration (stromal TILs: pâ¯=â¯0.67; intratumoral TILs: pâ¯=â¯0.14), and DFS rates (pâ¯=â¯0.17) were comparable between PP-PABC and non-PABC patients in global population. Similar results were found after stratification by pathological subtype. CONCLUSION: We observed similar patterns between postpartum PABC and control tumors in terms of chemosensitivity, immune infiltration, and prognostic. Our results enhance the idea that PP-PABC should receive the same standard of care treatment as other patients, including neoadjuvant chemotherapy.
Subject(s)
Breast Neoplasms/drug therapy , Lymphocytes, Tumor-Infiltrating/pathology , Neoadjuvant Therapy/methods , Pregnancy Complications, Neoplastic/drug therapy , Adult , Breast Neoplasms/immunology , Breast Neoplasms/pathology , Case-Control Studies , Disease-Free Survival , Female , Humans , Lymphocytes, Tumor-Infiltrating/immunology , Neoplasm Recurrence, Local/drug therapy , Postpartum Period , Pregnancy , Pregnancy Complications, Neoplastic/immunology , Pregnancy Complications, Neoplastic/pathology , Survival Rate , Treatment OutcomeABSTRACT
Preeclampsia is the most common cause of proteinuria with hypertension during pregnancy. Primary kidney disease and kidney disease secondary to systemic disorders may rarely occur during pregnancy, resulting in proteinuria. A 34-year-old woman was admitted to our hospital with abdominal distention and lower extremity edema. The pregnancy was terminated at the 24th week of gestation due to preterm labor. Even after the delivery, proteinuria and renal deterioration continued to progress. The M-peak was not found on serum and urine protein electrophoresis. The serum free light chains assay showed absolute elevation of lambda chains at 1013.9 mg/L with a decreased kappa to lambda ratio of 0.05. Kidney biopsy revealed light chain deposition disease with lambda light chain deposits on immunofluorescence. Bone marrow examination was compatible with multiple myeloma. To our knowledge, this is the first reported case of light chain deposition disease associated with multiple myeloma during pregnancy.
Subject(s)
Immunoglobulin kappa-Chains/analysis , Immunoglobulin lambda-Chains/analysis , Kidney Diseases/immunology , Kidney/immunology , Multiple Myeloma/immunology , Pregnancy Complications, Neoplastic/immunology , Adult , Biopsy , Female , Fluorescent Antibody Technique , Gestational Age , Humans , Immunoglobulin kappa-Chains/blood , Immunoglobulin lambda-Chains/blood , Kidney/physiopathology , Kidney/ultrastructure , Kidney Diseases/diagnosis , Microscopy, Electron , Multiple Myeloma/diagnosis , Obstetric Labor, Premature/etiology , Pregnancy , Pregnancy Complications, Neoplastic/diagnosis , Proteinuria/etiology , Proteinuria/physiopathology , StillbirthABSTRACT
While many investigators have described the biochemical and physiological similarities between tumor cells and trophoblast cells, in this discourse we will compare primarily their leucocytes, which constitute a large portion of the tumor and its microenvironment as well as the placenta and its microenvironment. There is a remarkable similarity between the cells that support placental growth and development and tumor growth and development. In many cases over half of the cells present in the tumor and the placenta are non-tumor or nontrophoblast cells, immune cells. Most of these immune cells are prevented from attacking the fetal derived placental cells and the self-derived tumor cells. Nevertheless, these leucocytes, in our opinion, are very active and support tumor and placental cell growth through the production of growth factors and angiogenic factors. These cells do this by activating the portion of the immune response which initiates and helps control tissue repair.
Subject(s)
Placenta/immunology , Pregnancy Complications, Neoplastic/immunology , Animals , Cell Growth Processes/immunology , Female , Humans , Pregnancy , Pregnancy Complications, Neoplastic/pathology , Tumor Microenvironment/immunologyABSTRACT
BACKGROUND: Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is a neuroautoimmune disease commonly associated with ovarian teratomas. It is characterized by neuropsychiatric symptoms, seizures, and autonomic instability. Few cases are described in pregnancy, and little is known about potential fetal effects. CASE: Anti-NMDA receptor encephalitis was diagnosed at 24 weeks of gestation. No improvement occurred with intravenous immunoglobulin, methylprednisolone, and plasmapheresis. Imaging was unremarkable. Cesarean delivery with concurrent bilateral oophorectomy resulted in prompt maternal improvement. Antibody titers were positive in cord blood. CONCLUSION: Anti-N-methyl-D-aspartate receptor encephalitis in pregnancy can lead to NMDA receptor antibodies in the fetal circulation. Pregnancy interruption through early delivery with or without oophorectomy may accelerate maternal recovery.
Subject(s)
Anti-N-Methyl-D-Aspartate Receptor Encephalitis/immunology , Antibodies/analysis , Fetus/immunology , Maternal-Fetal Exchange/immunology , Pregnancy Complications, Neoplastic/immunology , Adult , Female , Humans , Infant, Newborn , Male , Ovariectomy , Pregnancy , Pregnancy OutcomeABSTRACT
BACKGROUND: Tumour infiltrating lymphocytes (TILs) is one of the most exciting breast cancer biomarkers, yet no data is available on its prevalence in tumours diagnosed during pregnancy. METHODS: We evaluated the prevalence of TILs (stromal and intratumoural) in pregnant and non-pregnant young breast cancer patients. RESULTS: 11/116 (9.6%) of the non-pregnant and 2/86 (2.3%) pregnant patients had TILs ≥ 50% (p < 0.001) with highest prevalence observed in triple negative tumours (p = 0.01). CONCLUSIONS: This is the first report on TILs in tumours diagnosed during pregnancy. The low prevalence could reflect the state of low host immunity associated with pregnancy.
Subject(s)
Breast Neoplasms/immunology , Immunity, Cellular , Lymphocytes, Tumor-Infiltrating/cytology , Pregnancy Complications, Neoplastic/immunology , Adult , Breast Neoplasms/pathology , Female , Humans , Middle Aged , Pregnancy , Pregnancy Complications, Neoplastic/pathology , Young AdultSubject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Gonadal Steroid Hormones/immunology , Immunomodulation/physiology , Immunotherapy/methods , Melanoma/immunology , Melanoma/secondary , Melanoma/therapy , Molecular Targeted Therapy/methods , Pregnancy Complications, Neoplastic/immunology , Skin Neoplasms/immunology , Skin Neoplasms/therapy , Female , Humans , Male , PregnancyABSTRACT
Similarities between the pathologic progression of cancer and the physiologic process of placentation (eg, proliferation, invasion, and local/systemic tolerance) have been recognized for many years. Sex hormones such as human chorionic gonadotropin, estrogens, progesterone, and others contribute to induction of immunologic tolerance at the beginning of gestation. Sex hormones have been shown to play contributory roles in the growth of cancers such as breast cancer, prostrate cancer, endometrial cancer, and ovarian cancer, but their involvement as putative mediators of the immunologic escape of cancer is still being elucidated. Herein, we compare the emerging mechanism by which sex hormones modulate systemic immunity in pregnancy and their potentially similar role in cancer. To do this, we conducted a PubMed search using combinations of the following keywords: "immune regulation," "sex hormones," "pregnancy," "melanoma," and "cancer." We did not limit our search to specific publication dates. Mimicking the maternal immune response to pregnancy, especially in late gestation, might aid in design of better therapies to reconstitute endogenous antitumor immunity and improve survival.
Subject(s)
Gonadal Steroid Hormones/immunology , Immunomodulation/physiology , Melanoma/immunology , Pregnancy Complications, Neoplastic/immunology , Skin Neoplasms/immunology , Adult , Chorionic Gonadotropin/immunology , Chorionic Gonadotropin/metabolism , Chorionic Gonadotropin/therapeutic use , Estrogens/immunology , Estrogens/metabolism , Estrogens/therapeutic use , Female , Gestational Age , Gonadal Steroid Hormones/metabolism , Gonadal Steroid Hormones/therapeutic use , Humans , Immune System Phenomena/immunology , Immune System Phenomena/physiology , Immunologic Factors , Immunomodulation/immunology , Melanoma/drug therapy , Melanoma/pathology , Pregnancy , Pregnancy Complications, Neoplastic/drug therapy , Pregnancy Complications, Neoplastic/pathology , Progesterone/immunology , Progesterone/metabolism , Progesterone/therapeutic use , Prognosis , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Treatment OutcomeABSTRACT
Lymphomas account for less than 5% of thyroid malignant lesions. Vast majority of them are B-cell non-Hodgkin lymphomas (NHL), while Hodgkin lymphoma (HL) is extremely rare. Here we present two cases of HL, at baseline manifesting as a thyroid lesion. First patient, 29-year-old pregnant female, initially suspected for metastatic medullary thyroid cancer, was eventually diagnosed with mixed cellularity type of thyroid HL. Second patient, 22-year-old woman with suspicion of advanced thyroid cancer, was in the end diagnosed with an extra-lymphatic classical HL of the thyroid. In both cases, despite repeated fine-needle aspiration biopsy, cytological examination gave inconclusive or misleading results. On histopathological examination, thyroid tumor cells were positive for CD15 and CD30 antigen, which is typical for Reed-Sternberg cells. In the report authors also discuss difficulties in management as well as potential importance of novel methods such as FISH, PCR and other molecular techniques in diagnostics of thyroid lymphomas. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2896947559559648.
Subject(s)
Hodgkin Disease/pathology , Pregnancy Complications, Neoplastic/pathology , Thyroid Nodule/pathology , Adult , Biomarkers, Tumor/analysis , Biopsy, Fine-Needle , Diagnosis, Differential , Female , Fucosyltransferases/analysis , Hodgkin Disease/genetics , Hodgkin Disease/immunology , Hodgkin Disease/therapy , Humans , Immunohistochemistry , Ki-1 Antigen/analysis , Lewis X Antigen/analysis , Molecular Diagnostic Techniques , Predictive Value of Tests , Pregnancy , Pregnancy Complications, Neoplastic/genetics , Pregnancy Complications, Neoplastic/immunology , Pregnancy Complications, Neoplastic/therapy , Reed-Sternberg Cells/immunology , Reed-Sternberg Cells/pathology , Thyroid Nodule/genetics , Thyroid Nodule/immunology , Thyroid Nodule/therapy , Treatment Outcome , Young AdultABSTRACT
Monoclonal antibodies (mAbs) are the cornerstone of the treatment of several types of tumors, but their use in pregnant women is not clearly defined. Here, we report and analyze all available data on mAb treatment in pregnant cancer patients. A literature search was performed from 2000 until January 2013 and all articles addressing safety of mAbs during pregnancy were reviewed. We found very few data on the use of bevacizumab in pregnant women. However, owing to its antiangiogenic effects and possible consequences on fetal development, it should be avoided during pregnancy. Trastuzumab administration has been associated with an elevated incidence of oligohydramnios and poor neonatal outcomes, particularly when prescribed after the first trimester for repeated infusions, and therefore it is not recommended. Rituximab does not seem to be teratogenic, but a transient prolonged neutropenia in the newborns was reported, without major infectious consequences in most cases. Few data are available about other mAbs, and hence their use during pregnancy remains discouraged.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Immunotherapy/methods , Pregnancy Complications, Neoplastic/therapy , Animals , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Monoclonal, Murine-Derived/adverse effects , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Bevacizumab , Female , Fetal Development/drug effects , Humans , Molecular Targeted Therapy , Oligohydramnios/etiology , Pregnancy , Pregnancy Complications, Neoplastic/immunology , Risk Assessment , Rituximab , TrastuzumabABSTRACT
The diagnostic and prognostic role of thyroid ultrasound (TUS) in pregnant women positive for antibodies to thyroperoxidase (TPOAb) is unclear. The aim of our study was to compare the relation of ultrasound thyroid texture to the thyroid laboratory tests in pregnant women and controls. Using a semi-quantitative assessment we compared TUS in two groups of women with positive TPOAb and/or with thyroid dysfunction (TSH out of 0.06-3.67 mIU/L): 186 women in 1(st) trimester of pregnancy recruited from universal screening and 67 asymptomatic age-comparable non-pregnant non-postpartum women recruited from screening of general population (controls). Women with previous history of thyroid diseases were excluded. Only 64/131 (48.9 %) of TPOAb-positive pregnant women were TUS-positive (TUS with autoimmune pattern) in comparison with 35/49 (71.4 %) TPOAb-positive controls (p <0.011). Pregnant women had more often TSH >10.0 mIU/L if they were TPOAb-positive/TUS-positive as compared to those TPOAb-positive/TUS-negative (8/64 (12.5 %) vs. 0/67 (0 %), p = 0.009). The prevalence of preterm deliveries among TPOAb-positive women was significantly lower if TPOAb-positivity was not accompanied by TUS-positivity (2/67 (3.0 %) vs. 10/64 (15.6 %) in TPOAb-positive/TUS-positive women, p = 0.028). In conclusion, nearly half of the TPOAb-positive pregnant women did not have an autoimmune pattern in TUS. Normal TUS image in TPOAb-positive pregnant women might be a protective factor for preterm delivery.
Subject(s)
Autoantibodies/analysis , Iodide Peroxidase/antagonists & inhibitors , Iron-Binding Proteins/antagonists & inhibitors , Pregnancy Complications/immunology , Thyroid Gland/diagnostic imaging , Thyroid Gland/immunology , Thyroiditis, Autoimmune/diagnostic imaging , Thyroiditis, Autoimmune/immunology , Adult , Autoantigens/metabolism , Czech Republic/epidemiology , Female , Follow-Up Studies , Humans , Iodide Peroxidase/metabolism , Iron-Binding Proteins/metabolism , Mass Screening/methods , Organ Size , Pregnancy , Pregnancy Complications/diagnostic imaging , Pregnancy Complications/pathology , Pregnancy Complications/physiopathology , Pregnancy Complications, Neoplastic/diagnostic imaging , Pregnancy Complications, Neoplastic/immunology , Pregnancy Complications, Neoplastic/pathology , Pregnancy Complications, Neoplastic/physiopathology , Pregnancy Outcome , Pregnancy Trimester, First , Premature Birth/epidemiology , Premature Birth/etiology , Prevalence , Prospective Studies , Sensitivity and Specificity , Thyroid Gland/pathology , Thyroid Gland/physiopathology , Thyroid Nodule/diagnostic imaging , Thyroid Nodule/immunology , Thyroid Nodule/pathology , Thyroid Nodule/physiopathology , Thyroiditis, Autoimmune/pathology , Thyroiditis, Autoimmune/physiopathology , Thyrotropin/blood , UltrasonographyABSTRACT
Metastasis depends on the ability of tumor cells to establish a relationship with the newly seeded tissue that is conducive to their survival and proliferation. However, the factors that render tissues permissive for metastatic tumor growth have yet to be fully elucidated. Breast tumors arising during pregnancy display early metastatic proclivity, raising the possibility that pregnancy may constitute a physiological condition of permissiveness for tumor dissemination. Here we have shown that during murine gestation, metastasis is enhanced regardless of tumor type, and that decreased NK cell activity is responsible for the observed increase in experimental metastasis. Gene expression changes in pregnant mouse lung and liver were shown to be similar to those detected in premetastatic sites and indicative of myeloid cell infiltration. Indeed, myeloid-derived suppressor cells (MDSCs) accumulated in pregnant mice and exerted an inhibitory effect on NK cell activity, providing a candidate mechanism for the enhanced metastatic tumor growth observed in gestant mice. Although the functions of MDSCs are not yet understood in the context of pregnancy, our observations suggest that they may represent a shared mechanism of immune suppression occurring during gestation and tumor growth.
Subject(s)
Immune Tolerance/physiology , Immunosuppression Therapy , Myeloid Cells/physiology , Neoplasm Metastasis/immunology , Pregnancy Complications, Neoplastic/immunology , Pregnancy Complications, Neoplastic/pathology , Animals , Cell Line, Tumor , Female , Killer Cells, Natural/cytology , Killer Cells, Natural/immunology , Liver Neoplasms/secondary , Lung Neoplasms/secondary , Melanoma/pathology , Mice , Mice, Inbred C57BL , Mice, Inbred NOD , Mice, SCID , Myeloid Cells/cytology , Neoplasm Metastasis/pathology , Neoplasm Transplantation , PregnancySubject(s)
Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antibodies, Monoclonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Pregnancy Complications, Neoplastic/drug therapy , Antibodies, Monoclonal, Humanized , Antigens, Neoplasm/immunology , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Contraindications , Female , Fetal Development/drug effects , Humans , Placental Circulation , Pregnancy , Pregnancy Complications, Neoplastic/immunology , Rituximab , Toxicity Tests/trends , TrastuzumabABSTRACT
Rare cases of possible materno-fetal transmission of cancer have been recorded over the past 100 years but evidence for a shared cancer clone has been very limited. We provide genetic evidence for mother to offspring transmission, in utero, of a leukemic cell clone. Maternal and infant cancer clones shared the same unique BCR-ABL1 genomic fusion sequence, indicating a shared, single-cell origin. Microsatellite markers in the infant cancer were all of maternal origin. Additionally, the infant, maternally-derived cancer cells had a major deletion on one copy of chromosome 6p that included deletion of HLA alleles that were not inherited by the infant (i.e., foreign to the infant), suggesting a possible mechanism for immune evasion.